Barriers for access to cannabidiol as a treatment option for children with neuro-diverse disabilities: A qualitative key informants method - 24/05/23
Highlights |
• | Explores the opinions of both parents and health care professionals within the same community about Cannabidiol as a treatment and the barriers. |
• | This study finds that parents’ process for accessibility varies and struggles due to stigma, costs, resistance from the community, and lack of education on Cannabidiol (CBD). |
• | Health care professionals advocate for more research and education while they worry about stigma within the medical community and professional and licensing risks with recommending treating children using Cannabidiol. |
• | Parents and health care professionals are challenged with the resistance of support toward the use of medical cannabis from the political and professional community. |
• | Lack of research regarding safety and efficacy guidelines of medical cannabis for children directly influences policy treatment and licensing risks for professionals. |
Summary |
Background |
Canada legalized medical cannabis in 2001. There is a significant concern about prescribing cannabidiol to children, and the largest is the effects on the developing brain in a child 25 years old or younger. There are growing anecdotal findings that cannabidiol is an alternate treatment option for children with neurodiverse disabilities. Parents and health professionals working with medical cannabis often face access barriers.
Objective |
This study explores the policy barriers for parents of neuro-diverse children and their health care supporters in accessing cannabidiol as a treatment in British Columbia, Canada.
Design |
This ethnographic study used the purposive key informants’ interview method to describe their experiences with medical cannabis access for children with neurodiverse disabilities.
Setting(s) |
British Columbia, Canada.
Participants |
Key informants included seven medical community cannabis professionals and seven family participants treating their neuro-diverse children with cannabidiol.
Methods |
Data were subjected to qualitative content analysis to identify patterns and themes.
Results |
Analysis of all data revealed six common barriers “Costs Associated with Cannabidiol Treatments”, “Education on the Subject and Going through Their Networks to Self-Educate”, “Lack of Research and Medical Studies”, and “Adverse Events and Risks Associated with First-line Pharmaceutical Treatments”.
Conclusions |
Themes revealed barriers of stigma and resistance from the family experience with community members and the medical community. Professionals reported a lack of support from their peers, stigma and concerns with licensing/professional risks when treating children 25 years and younger using cannabidiol. Findings show opportunities for change in accessing medical cannabis for the pediatric population in British Columbia, Canada.
Le texte complet de cet article est disponible en PDF.Keywords : Autism, Health Care Barriers, Medical Cannabis, Pediatric Neurological Disability, Qualitative Study, Stigmatization
Abbreviation : CBD
Plan
Vol 28
Article 100904- juin 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?